[HTML][HTML] Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on …
YW Zhao, S Liu, H Qin, JB Sun, M Su, GJ Yu… - Frontiers in …, 2023 - frontiersin.org
Objective: This study aimed to prospectively observe the efficacy and safety of CalliSpheres
drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) for refractory non …
drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) for refractory non …
[HTML][HTML] Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
Q Zhu, R Ni, X Guan - Translational Lung Cancer Research, 2023 - ncbi.nlm.nih.gov
Background The health expenditure on treatment of advanced non-small cell lung cancer
(NSCLC) is enormous, especially in third-line or further therapy. Cost-effectiveness analysis …
(NSCLC) is enormous, especially in third-line or further therapy. Cost-effectiveness analysis …
[HTML][HTML] Novel agents or combinations in recurrent or metastatic nasopharyngeal cancer
E IO, ESH CLL - memoinoncology.com
Nasopharyngeal cancer (NPC) is a rare malignancy with an incidence of approximately
133,000 annually worldwide, resulting in about 80,000 deaths per year [1]. Whereas early …
133,000 annually worldwide, resulting in about 80,000 deaths per year [1]. Whereas early …